1. M. S. Okun, L. A. Boothby, R. B. Bartfield, and P. L. Doering, “GHB: An important pharmacologic and clinical update,” J. Pharm. Pharm. Sci., 4, No. 2, 167–175 (2001).
2. V. Crunelli, Z. Emri, and N. Leresche, “Unravelling the brain targets of γ-hydroxybutyric acid,” Curr. Opin. Pharmacol., 6, No. 1, 44–52 (2006).
3. V. P. Barkhatova and I. A. Zavalishin, “Neurotransmitter organization of motor systems of the brain and spinal cord in the norm and under conditions of pathologies,” Korsakov Zh. Nevrol. Psikhiat., 1, No. 8, 5–13 (2004).
4. V. V. Zakusov, Sodium Oxybutyrate: Neuropharmacological and Clinical Examination, Meditsina, Moscow (1968).
5. J. C. Rekling, G. D. Funk, D. A. Bayliss, et al., “Synaptic control of motoneuronal excitability,” Physiol. Rev., 80, No. 2, 767–852 (2000).